Molecular basis for specificity in the druggable kinome: Sequence-based analysis

Bioinformatics

Volumn 23, Issue 5, 2007, Pages 563-572

  Chen, Jianping ^a   Zhang, Xi ^a   Fernández, Aiel ^a,b,c  

^a RICE UNIVERSITY   (United States)

^b Rice University   (United States)

^c THE UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; ABELSON KINASE; ADENOSINE TRIPHOSPHATE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; AURORA A KINASE; AURORA B KINASE; CANERTINIB; CYCLIN DEPENDENT KINASE 2; DEATH ASSOCIATED PROTEIN KINASE; DORAMAPIMOD; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLAVOPIRIDOL; GEFITINIB; IMATINIB; LAPATINIB; PELITINIB; PHOSPHOTRANSFERASE INHIBITOR; PREGNANE X RECEPTOR; ROSCOVITINE; RUBOXISTAURIN; SOLVENT; SORAFENIB; SUNITINIB; UNINDEXED DRUG; VANDETANIB; VATALANIB;

ACCURACY; ARTICLE; BINDING SITE; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME LOCALIZATION; ENZYME STRUCTURE; HYDROGEN BOND; LIGAND BINDING; MICROENVIRONMENT; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS;

EID: 34047098911     PISSN: 13674803     EISSN: 13674811     Source Type: Journal    
DOI: 10.1093/bioinformatics/btl666     Document Type: Article

References (26)

1. Bain,J. et al. (2003) The specificities of protein kinase inhibitors: An update. Biochem. J., 371, 199-204.
2. Bonneau,R. et al. (2002) De novo prediction of three-dimensional structures for major protein families. J. Mol. Biol., 322, 65-78.
3. Braken,C. et al. (2004) Combining prediction, computation and experiment for the characterization of protein disorder. Curr. Opin. Struct. Biol., 14, 570-576.
4. Chivian,D. et al. (2005) Prediction of CASP6 structures using automated Robetta protocols. Proteins, 61 (Suppl. 7), 157-166 (Supplementary Material).
5. Chothia,C. (1974) Hydrophobic bonding and accessible surface area in proteins. Nature, 248, 338-339.
6. Dietz,A.B. et al. (2004) Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood, 104, 1094-1099.
7. Druker,B.J. (2004) Molecularly targeted therapy: Have the floodgates opened? Oncologist, 9, 357-360.
8. Escriva,H. et al. (2000) Ligand binding and nuclear receptor evolution. Bioessays, 22, 717-727.
9. Fabian,M.A. et al. (2005) A small molecule kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol., 23, 329-336.
10. Feng,B.Y. et al. (2005) High throughput assays for promiscuous inhibitors. Nat. Chem. Biol., 1, 146-148.
11. Fernández,A. (2004) Keeping dry and crossing membranes. Nat. Biotech., 22, 1081-1084.
12. Fernández,A. and Berry,R.S. (2004) Molecular dimension explored in evolution to promote proteomic complexity. Proc. Natl Acad. Sci. USA, 101, 13460-13465.
13. Fernández,A. and Maddipati,S. (2006) A priori inference of cross reactivity for drug-targeted kinases. J. Med. Chem., 49, 3092-3100.
14. Fernández,A. et al. (2002) Dynamics of hydrogen bond desolvation in protein folding. J. Mol. Biol., 321, 659-675.
15. Fraczkiewicz,R. and Braun,W. (1998) Exact and efficient analytical calculation of the accessible surface areas and their gradient for macromolecules. J. Comput. Chem., 19, 319-333.
16. Higgins,D.G. et al. (1996) Using CLUSTAL for multiple sequence alignments. Methods Enzymol., 266, 383-402.
17. Hogue,C.W.V. (1997) Cn3D: A new generation of three-dimensional molecular structure viewer. Trends Biochem. Sci., 22, 314-316.
18. Hopkins,A.L. et al. (2006) Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol., 16, 127-136.
19. Huse,M. and Kuriyan,J. (2002) The conformational plasticity of protein kinases. Cell, 109, 275-282.
20. Knight,Z.A. and Shokat,K.M. (2005) Features of selective kinase inhibitors. Chem. Biol., 12, 621-637.
21. Ma,B. et al. (2003) Protein-protein interactions structurally conserved residues distinguish between binding sites and exposed protein surfaces. Proc. Natl Acad. Sci. USA, 100, 5772-5777.
22. Manning,G. et al. (2002) The protein kinase complement of the human genome. Science, 298, 1912-1934.
23. Ooi,T. et al. (1987) Accessible surface area as a measure of the thermodynamic parameters of hydration of peptides. Proc. Natl Acad. Sci. USA, 84, 3086-3090.
24. Shenkin,S.P. et al. (1991) Information-theoretical entropy as a measure of sequence variability. Proteins: Struct. Funct. Genet., 11, 297-313.
25. Vieth,M. et al. (2004) Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim. Biophys. Acta, 1697, 243-257.
26. Whittle,P.J. and Blundell,T.L. (1994) Protein structure-based drug design. Annu. Rev. Biophys. Biomol. Str., 23, 349-375.